Provides insurance coverage for cranial prostheses for a diagnosed health condition, chronic illness, or injury.
S04961 would require certain New York health insurance policies and contracts that already cover prostheses to also cover cranial prostheses, defined in the bill as wigs or hairpieces, for people experiencing temporary or permanent medical hair loss. The coverage would apply when a licensed provider prescribes the cranial prosthesis as part of treatment for a diagnosed health condition, chronic illness, or injury, including examples such as alopecia areata, alopecia medicamentosa, scarring alopecia, and lupus.
The bill sets several limits on the benefit: coverage would be available no more than once every 12 months, capped at $750 per instance, and subject to any otherwise applicable cost-sharing requirements. It amends multiple sections of the Insurance Law so the mandate applies to individual policies, group or blanket policies, and certain hospital service corporations, health service corporations, and medical expense indemnity funds. The bill would take effect immediately and apply to policies issued, delivered, renewed, or modified on or after the effective date.
The bill would expand mandated insurance benefits in New York by adding cranial prostheses to the list of covered prosthetic services for insurers and health plans that already cover prostheses. It would amend Insurance Law sections 3216, 3221, and 4303, thereby affecting individual health insurance policies, group or blanket policies, and certain nonprofit health coverage entities. Insurers would need to update coverage terms and claims processing to include medically necessary wigs or hairpieces for qualifying hair loss conditions, subject to the bill’s annual frequency limit, dollar cap, and cost-sharing rules.
The available voting history suggests generally favorable sentiment toward the bill. The Senate Insurance Committee approved it unanimously, 11-0, indicating broad support among committee members. No committee transcript was provided, so there is no recorded debate to indicate opposition or reservations in the materials supplied.
The main policy questions likely concern the cost and scope of the mandate, rather than whether medical hair loss should be covered at all. Potential points of contention include the $750 cap, the once-per-12-month limitation, and the requirement that coverage only apply when prescribed by a licensed provider for a diagnosed condition, chronic illness, or injury. Insurers may be concerned about added premium or administrative costs, while supporters are likely to emphasize access and affordability for patients facing hair loss from conditions such as alopecia or lupus.